Expert Insights into the Treatment of Myelofibrosis

Srdan Verstovsek, MD, PhD, provides an overview of how myelofibrosis is diagnosed and what criteria are used for risk stratification.

Aaron Gerds, MD, explains the various types of myelofibrosis and the underlying pathophysiologies.

Raajit Rampal, MD, describes the JAK-STAT pathway and how it’s fundamental to all types of myelofibrosis.

Dr John Mascarenhas presents a patient case scenario of a 68-year-old woman with a common presentation of primary myelofibrosis.

A review of the approved treatments for myelofibrosis, including dosing guidelines and supporting clinical trial data.

Raajit Rampal, MD, PhD, shares the treatment options he would consider for the presented clinical scenario.

A panel of experts considers treatment options for patients with myelofibrosis based on platelet counts, while factoring in health insurance barriers.

John Mascarenhas, MD, presents a clinical scenario of a 73-year-old man with myelofibrosis and a low platelet count.

A discussion on when to switch a patient with myelofibrosis to a new JAK inhibitor treatment, and possible strategies for transitioning.

Raajit Rampal, MD, explains how he considers safety profiles when deciding on appropriate treatment for myelofibrosis and how he manages toxicities for patients.

Dr Srdan Verstovsek shares how he assesses myelofibrosis treatment response in his clinical practice.

A look at sequencing strategies for myelofibrosis treatments.

Experts delve into the unmet needs in the myelofibrosis treatment landscape and highlight promising ongoing clinical trials.

The panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.